WALTHAM, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018.
Information on the presentation is as follows:
|Event:||Goldman Sachs 39th Annual Global Healthcare Conference|
|Date:||Tuesday, June 12, 2018|
|Time:||10:40 a.m. PDT|
|Location:||Terranea Resort, Rancho Palos Verdes, CA|
A live webcast of the presentation will be available by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact:
Elhan Webb, CFA